DHC is a real estate investment trust focused on owning high-quality healthcare properties located throughout the United States. DHC seeks diversification across the health services spectrum by care delivery and practice type, by scientific research disciplines and by property type and location. As of March 31, 2025, DHC’s approximately $6.8 billion portfolio included 343 properties in 34 states and Washington, D.C., with more than 26,000 senior living units, approximately 7.6 million square feet of medical office and life science properties and occupied by approximately 450 tenants. DHC is managed by The RMR Group (Nasdaq: RMR), a leading U.S. alternative asset management company with approximately $40 billion in assets under management as of March 31, 2025 and more than 35 years of institutional experience in buying, selling, financing and operating commercial real estate. DHC is headquartered in Newton, MA.
Portfolio Dynamics | Explore DHC's diverse healthcare real estate portfolio, featuring senior living communities and medical offices, as it navigates mixed segment performance and strategic dispositions. |
Financial Challenges | Delve into DHC's financial landscape, marked by revised NOI guidance, negative EPS, and a complex debt structure, as it strives for operational efficiency. |
Market Positioning | Learn how DHC's market valuation reflects both its challenges and potential, with a Core FFO multiple of 27x against a peer average of 23x, and a cautious analyst outlook. |
Strategic Outlook | Discover DHC's efforts to optimize its portfolio through asset sales and operational improvements, balancing near-term financial pressures with long-term growth prospects. |
Metrics to compare | DHC | Sector Sector - Average of metrics from a broad group of related Real Estate sector companies | Relationship RelationshipDHCPeersSector | |
---|---|---|---|---|
P/E Ratio | −2.8x | 24.6x | 9.1x | |
PEG Ratio | −0.15 | 0.26 | 0.01 | |
Price/Book | 0.4x | 2.0x | 0.9x | |
Price / LTM Sales | 0.5x | 6.9x | 3.9x | |
Upside (Analyst Target) | 10.6% | 2.4% | 12.6% | |
Fair Value Upside | Unlock | −16.2% | 0.4% | Unlock |